Graph Therapeutics, a Vienna-based biotechnology company, has successfully secured $5 million in a new funding round led by the venture capital firm Daphni. This latest investment boosts the company's total funding to over $10 million, including non-dilutive grants. The capital is earmarked to accelerate the development of its internal pipeline of drugs targeting inflammatory and immune-mediated diseases.
Strategic Investment to Propel Drug Discovery
The new financing saw Paris-based Daphni join an established syndicate of investors, including SquareOne, Merantix Capital, and NAVEC Investment Management. This investment is further supplemented by non-dilutive grant funding from the Austrian Research Promotion Agency (FFG) and Austria Wirtschaftsservice (AWS). This combined financial backing underscores strong confidence in Graph's mission to develop differentiated medicines for complex immune disorders.
With its platform technology now substantially de-risked and validated, Graph is poised to advance its internal drug discovery programs. The company will leverage the new funds to scale investment into its asset programs focused on immune and inflammatory conditions. This maturity also positions Graph to explore strategic out-licensing opportunities and partnerships, extending the platform's value beyond its proprietary pipeline.
A New Generation of Techbio
Sofia Dahoune, a Partner at Daphni, highlighted Graph's position as a next-generation techbio company where deep technological innovation is integrated with rigorous research. She noted that the complexity of immune-mediated diseases requires such a multifaceted approach. Daphni's investment reflects its excitement to support the Graph team as they transition into developing therapeutic assets.
Gregory Vladimer, co-founder and CEO of Graph Therapeutics, stated that the company's platform has reached a critical inflection point. It is now generating actionable biological insights that directly inform its drug discovery initiatives. He emphasized that this new backing provides the urgency to pursue precision medicines and demonstrate how decoding immune dysfunction reveals disease drivers.
Innovative Platform Technology
Graph's pioneering platform integrates sophisticated live patient cell models with advanced machine learning to decode complex immune system dysfunction. The company applies a lab-in-the-loop perturbation approach to primary patient cell samples and analyzes multi-omics data. This process enables the identification of novel disease mechanisms, potential drug targets, and crucial biomarkers for immune-mediated diseases.
The company's methodology builds upon the founding team's extensive experience in pioneering AI-driven precision oncology at Allcyte, which was later acquired by Exscientia. This proven track record in applying advanced computational techniques to complex biology provides a strong foundation for their current work. Graph is now applying this expertise to the intricate challenges presented by immunology and inflammatory conditions.
Strong Support from Austrian Innovation Ecosystem
The company's financial foundation is also strengthened by significant non-dilutive grant awards from Austria's premier innovation agencies. These include grants from the FFG's Austrian Life Sciences program and the AWS Deep Tech Life Sciences Seed Financing program. This public funding serves as an independent validation of Graph's scientific strategy and highlights the robust support within Austria's deep tech ecosystem.
This latest $5 million investment marks a pivotal moment for Graph Therapeutics, providing the necessary resources to scale its operations and advance its therapeutic programs. With the combined support of venture capital and public grants, the company is well-positioned to translate its innovative platform into tangible precision medicines. The industry will be watching closely as Graph works to redefine the treatment of complex immune-mediated diseases.